Back

New Board Member - Chris Ground

February 11, 2025

AUSTIN, TX (January 14, 2025) – Prodigy Health proudly announces the appointment of Chris Ground to its Board of Advisors. With over three decades of experience in the medical industry, Mr. Ground brings an exceptional track record of leadership, innovation, and operational excellence. His roles at FFF Enterprises—where he served as both Chief Operating Officer (COO) and Chief Commercial Officer (CCO)—solidified the company’s position as a trusted distributor of plasma products, vaccines, and critical-care biopharmaceuticals.

Mr. Ground began his career at Bristol Laboratories in 1982 as a Sales Representative. He then joined Cutter Biological (later Bayer Biologicals), where he was instrumental in launching notable therapies, including Gamimune N, Prolastin, and Kogenate. During his 12-year tenure, he ascended through various positions—Field Sales Representative, Trainer, Training Manager, and Biological Division Business Manager—before earning an MBA from Claremont Graduate University in 1998.

As part of FFF Enterprises, Mr. Ground led numerous strategic initiatives that propelled growth and enhanced the company’s reputation for delivering vital healthcare products nationwide. His expertise in operations and commercial strategy aligns seamlessly with Prodigy Health’s core values of data-driven insight, forward-thinking innovation, and genuine compassion.

“Chris has played a pivotal role in shaping best-in-class healthcare services and operations,” said Dean Bourque, VP of Operations & Technology. “We’re excited to leverage his depth of knowledge and passion for excellence as we continue revolutionizing specialty pharmaceutical distribution with human touch, advanced technology, and integrity. Chris’s addition to our Board of Advisors underscores our commitment to expanding and refining our offerings, ensuring we deliver the most reliable, efficient, and patient-focused solutions in the market.”